Revision: Feb. 25, 2026, 11:31 a.m.
Rep. Kesselring, Hills. 18
Rep. Kofalt, Hills. 32
Rep. Mazur, Hills. 44
Rep. Cole, Hills. 26
Rep. Miles, Hills. 12
February 11, 2026
2026-0666h
05/07
Amendment to HB 1734-FN
Amend RSA 126-ZZ:3 as inserted by section 2 of the bill by inserting after paragraph IV the following new paragraph:
V. Nothing in this chapter shall prohibit an experimental treatment center from conducting clinical research protocols. Clinical research protocols may be approved by an institutional review board (IRB) meeting pursuant to 45 C.F.R. Part 46 or by a scientific review board established under this chapter. Research protocols may employ any study design, participant stratification, outcome measurement, or monitoring approach consistent with the protocol's scientific and ethical justification. Clinical research conducted under this section shall maintain all study records, including protocols, consent forms, case reports, and safety data, for not less than 3 years and shall make such records available to state or federal regulatory authorities upon reasonable request or where disclosure is required by law or regulation. Sites conducting research under this chapter consent to inspection by state or federal regulatory authorities, at reasonable times and upon reasonable request, as necessary to verify compliance with applicable requirements.
Amend RSA 126-ZZ:5, IV as inserted by section 2 of the bill by replacing it with the following:
IV. Authorized providers may administer experimental treatments to eligible patients pursuant to RSA 126-ZZ:2, II if reviewed and approved by a scientific review board established under this chapter. The scientific review board shall determine the appropriate quality standards, documentation requirements, and clinical oversight for each treatment protocol, which may include quality frameworks and documentation standards recognized by international regulatory authorities. The scientific review board shall include not fewer than 3 members with appropriate expertise and shall include at least one licensed physician and at least one member with experience in clinical outcomes research. Providers may share scientific review boards or board members with other authorized facilities or with academic institutions.
Amend RSA 126-ZZ:6, I as inserted by section 2 of the bill by replacing it with the following:
I. Authorized experimental treatment centers may manufacture drugs, biologics, or devices on-site or through contracted facilities, provided the center's scientific review board approves the manufacturing protocol and determines it meets quality standards equivalent to recognized pharmaceutical manufacturing frameworks for patient safety. The scientific review board shall determine the appropriate quality framework for manufacturing and compounding under this chapter for purposes of clinical use in experimental treatment centers.
Amend RSA 126-ZZ:6 as inserted by section 2 of the bill by inserting after paragraph IV the following new paragraph:
V. Nothing in this section shall be construed to alter the jurisdiction or authority of the board of pharmacy under RSA 318.